查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1416345

KRAS 抑制劑市場報告：2030 年趨勢、預測和競爭分析

KRAS Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

KRAS 抑制劑的趨勢和預測

預計2024年至2030年全球KRAS抑制劑市場將以32.5%的複合年成長率成長。該市場的主要驅動力是不同類型癌症中KRAS突變的盛行率不斷增加、正在進行的臨床試驗數量的快速增加以及對精準醫療和個人化癌症治療的投資的增加。全球KRAS抑制劑市場前景廣闊，臨床實驗室、癌症診斷中心、醫院、癌症研究機構和學術機構市場充滿機會。

KRAS抑制劑市場洞察

Lucintel 預測，由於肺癌患者 KRW 突變盛行率急劇上升，以及人們對肺癌治療研究的關注度增加，肺癌在預測期內將經歷最高成長。

由於臨床研究的增加以及研究機構和生物技術公司之間合作夥伴關係的擴大，癌症研究機構將繼續成為該市場的最大部分。

由於癌症發生率高且該地區有主要企業，北美在整個預測期內可能仍然是最大的地區。

常問問題

Q1.市場成長預測是多少：

A1. 2024年至2030年，全球KRAS抑制劑市場預計將以32.5%的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 該市場的主要驅動力是不同癌症類型中 KRAS 突變的流行、正在進行的臨床試驗數量的快速增加以及對精準醫療和個性化癌症治療的投資的增加。

Q3.市場的主要細分市場是：

A3. 全球KRAS抑制劑市場前景廣闊，臨床實驗室、癌症診斷中心、醫院、癌症研究機構和學術機構市場充滿機會。

Q4.市場的主要企業是：

A4. 一些主要的 KRAS 抑制劑公司是：

  • Amgen
  • Boehringer Ingelheim
  • Bridgebio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預測，由於肺癌患者中 KRW 突變的盛行率急劇上升，人們越來越關注肺癌治療方法的研究，肺癌將在預測期內經歷最高的成長。

Q6.未來五年預計哪些地區的市場成長最大？

答：由於癌症發生率高且主要企業在該地區的存在，北美在整個預測期內仍將是最大的地區。

Q7. 可以客製化報告嗎？

A6. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球 KRAS 抑制劑市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球KRAS抑制劑市場趨勢（2018-2023）與預測（2024-2030）
  • 按癌症類型分類的全球 KRAS 抑制劑市場
    • 肺癌
    • 胰臟癌
    • 大腸直腸癌
    • 其他
  • 全球 KRAS 抑制劑市場（按最終用途）
    • 臨床實驗室
    • 癌症診斷中心
    • 醫院
    • 癌症研究組織
    • 學術機構
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球KRAS抑制劑市場區域分佈
  • 北美KRAS抑制劑市場
  • 歐洲KRAS抑制劑市場
  • 亞太地區 KRAS 抑制劑市場
  • 其他地區KRAS抑制劑市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按癌症類型分類的全球 KRAS 抑制劑市場成長機會
    • 全球 KRAS 抑制劑市場成長機會（以最終用途）
    • 全球 KRAS 抑制劑市場成長機會（按地區）
  • 全球KRAS抑制劑市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球KRAS抑制劑市場產能擴張
    • 全球 KRAS 抑制劑市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Amgen
  • Boehringer Ingelheim
  • BridgeBio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology
簡介目錄

KRAS Inhibitors Trends and Forecast

The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets. The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030. The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.

A more than 150-page report is developed to help in your business decisions.

KRAS Inhibitors by Segment

The study includes a forecast for the global KRAS inhibitors by cancer type, end use, and region.

KRAS Inhibitors Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

KRAS Inhibitors Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Clinic Laboratories
  • Cancer Diagnostic Centers
  • Hospitals
  • Cancer Research Institutes
  • Academic Institutions
  • Others

KRAS Inhibitors Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of KRAS Inhibitors Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies KRAS inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the KRAS inhibitors companies profiled in this report include-

  • Amgen
  • Boehringer Ingelheim
  • Bridgebio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology

KRAS Inhibitors Market Insights

Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.

Within this market, cancer research institutes will remain the largest segment due to the rising number of clinical research along with growing partnerships among research institutes and biotech companies.

North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.

Features of the Global KRAS Inhibitors Market

Market Size Estimates: KRAS inhibitors market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: KRAS inhibitors market size by cancer type, end use, and region in terms of value ($B).

Regional Analysis: KRAS inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer types, end uses, and regions for the KRAS inhibitors market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the KRAS inhibitors market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for KRAS inhibitors market?

Answer: The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the KRAS inhibitors market?

Answer: The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.

Q3. What are the major segments for KRAS inhibitors market?

Answer: The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets.

Q4. Who are the key KRAS inhibitors market companies?

Answer: Some of the key KRAS inhibitors companies are as follows:

  • Amgen
  • Boehringer Ingelheim
  • Bridgebio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology

Q5. Which KRAS inhibitors market segment will be the largest in future?

Answer: Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.

Q6. In KRAS inhibitors market, which region is expected to be the largest in next 5 years?

Answer:North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the KRAS inhibitors market by cancer type (lung cancer, pancreatic cancer, colorectal cancer, and others), end use (clinic laboratories, cancer diagnostic centers, hospitals, cancer research institutes, academic institutions, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global KRAS Inhibitors Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global KRAS Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global KRAS Inhibitors Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Pancreatic Cancer
    • 3.3.3: Colorectal Cancer
    • 3.3.4: Others
  • 3.4: Global KRAS Inhibitors Market by End Use
    • 3.4.1: Clinic Laboratories
    • 3.4.2: Cancer Diagnostic Centers
    • 3.4.3: Hospitals
    • 3.4.4: Cancer Research Institutes
    • 3.4.5: Academic Institutions
    • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global KRAS Inhibitors Market by Region
  • 4.2: North American KRAS Inhibitors Market
    • 4.2.2: North American KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
  • 4.3: European KRAS Inhibitors Market
    • 4.3.1: European KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
    • 4.3.2: European KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
  • 4.4: APAC KRAS Inhibitors Market
    • 4.4.1: APAC KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
    • 4.4.2: APAC KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
  • 4.5: ROW KRAS Inhibitors Market
    • 4.5.1: ROW KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
    • 4.5.2: ROW KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global KRAS Inhibitors Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global KRAS Inhibitors Market by End Use
    • 6.1.3: Growth Opportunities for the Global KRAS Inhibitors Market by Region
  • 6.2: Emerging Trends in the Global KRAS Inhibitors Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global KRAS Inhibitors Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global KRAS Inhibitors Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Amgen
  • 7.2: Boehringer Ingelheim
  • 7.3: BridgeBio Pharma
  • 7.4: Erasca
  • 7.5: Innovent Biologics
  • 7.6: Incyte
  • 7.7: Mirati Therapeutics
  • 7.8: Novartis
  • 7.9: Jemincare
  • 7.10: Cardiff Oncology